Radiometal-binding peptide analogues

Details Radiometal-binding peptide analogues Radiometal-binding peptide analogues

2006-05-16

2006-05-16

Wessendorf, T. D. (Department: 1639)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S300000, C530S317000, C530S324000, C530S333000, C530S334000, C530S335000, C530S336000, C424S001690, C424S001110, C424S001570, C424S001650, C424S009100, C514S002600

Reexamination Certificate

active

07045503

ABSTRACT:
Novel metal binding ligands are disclosed that may be coupled to peptides for use in methods of diagnosis and therapy. Peptides containing the ligands are produced using a method wherein ligand introduction or cyclization can be conducted at any point during the synthesis of the peptide. Such peptide derivatives are readily labeled with radiometals, such as isotopes of rhenium or technetium, while retaining their ability to tightly bind specific peptide receptors.

REFERENCES:
patent: 4564472 (1986-01-01), Ueda et al.
patent: 4822890 (1989-04-01), Bolin
patent: 5080884 (1992-01-01), McBride et al.
patent: 5225180 (1993-07-01), Dean et al.
patent: 5227474 (1993-07-01), Johnson et al.
patent: 5449761 (1995-09-01), Belinka, Jr. et al.
patent: 5539138 (1996-07-01), Flanagan et al.
patent: 5556939 (1996-09-01), Flanagan et al.
patent: 5746996 (1998-05-01), Govindan et al.
patent: 5753206 (1998-05-01), McBride et al.
patent: 5772981 (1998-06-01), Govindan et al.
patent: 0 536 741 (1993-04-01), None
patent: 91/01144 (1991-02-01), None
patent: 93/21962 (1993-11-01), None
patent: 93/25244 (1993-12-01), None
patent: 94/23758 (1994-10-01), None
patent: 94/26294 (1994-11-01), None
patent: 94/28942 (1994-12-01), None
patent: 96/40756 (1996-12-01), None
Virgolini et al., “Vasoactive Intestinal Peptide-Receptor Imaging for the Localization of Intestinal Adenocarcinomas and Endocrine Tumors”The New England Journal of Medicinepp. 1116-1121 (1994).
Virgolini et al., “Vasoactive Intestinal Peptide Receptor Scintigraphy”The Journal of Nuclear Medicine36:1732-1739 (1995).
Lister-Jamcs et al., “Radiopharmaceutical Chemistry: Protein, Peptides, Antibodies I” No. 370 36:91P, (1995).
Pearson et al., “Somatostatin Receptor-Binding Peptides Labeled with Technetium-99m: Chemistry and Initial Biological Studies”J. Med. Chem.39:1361-1371 (1996).
Krenning et al., “Somatostatin Receptor Scintigraphy with Indium-111-DTPA-D-Phe-1-Octreotide in Man: Metabolism, Dosimetry and Comparison with Iodine-123-TYr-3-Octreotide”The Journal of Nuclear Medicin33:652-658 (1992).
Wraight et al., “The use of a chelating derivative of alpha melanocyte stimulating hormone for the clinical imaging of melanoma”The British Journal of Radiology65:112-118 (1992).
Reubi, “In Vitro Identification of Vasoactive Intestinal Peptide Receptors in Human Tumors: Implications for Tumor Imaging”The Journal of Nuclear Medicine36:1846-1853 (1995).
Maina et al., “Synthesis, Radiochemical and Biological Evaluation of99mTc[N4(D)Phe1]-Octreotide, a New Octreotide Derivative with High Affinity for Somatostatin Receptor”The Journal of Nuclear Biology and)Medicinepp. 452 (1994.
Bajusz et al., “Highly potent metallopeptide analogues of luteinizing hormone-releasing hormone” Proc. Natl. Acad. Sci. USA 86:6313-6317 (1989).
Felix et al., “Synthesis, biological activity and conformational analysis of cyclic GRF analogs” J. Peptide Protein Res. 32:441-454 (1988).
Edwards et al., “Generally Applicable, Convenient Solid-Phase Synthesis and Receptor Affinities of Octreotide Analogs”J. Med. Chem.37:3749-3757 (1994).
Beinstock et al., “Conformational Analysis of a Highly Potent Dicyclic Gonadotropin-Releasing Hormone Antagonist by Nuclear Magnetic Resonance and Molecular Dynamics”American Chemical Societypp. 3265-3273 (1993).
Barbacci et al., “The Structural Basis for the Specificity of Epidermal Growth Factor and Heregulin Binding” The Journal of Biological Chemistry 270:9585-9589 (1995).
Haskell-Luevano et al., “Characterizations of the Unusual Dissociation Properties of Melanotropin Peptides from the Melanocortin Receptor, hMC1R”J. Med. Chem.39:432-435 (1996).
Al-Obeidi et al., “Design of a New Class of Superpotent Cyclic α-Melanotropins Based on Quenched Dynamic Simulations”J. AM. Chem. Soc.111:3413-3416 (1989).
O'Donnell et al., “Ro 25-1553: A Novel, Long-Acting Vasoactive Intestinal Peptide Agonist. Part I: In Vitro and In Vivo Bronchodilator Studies” The Journal of Pharmacology and Experimental Therapeutics 270:1282-1294 (1994).
Virgolini et al., “Cross-Competition between Vasoactive Intestinal Peptide and Somatostatin for Binding to Tumor Cell Membrane Receptors1”Cancer Researchpp. 690-700 (1994).

Affiliated with

Also associated with

Rating

Radiometal-binding peptide analogues does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Radiometal-binding peptide analogues, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Radiometal-binding peptide analogues will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3624415